Printer Friendly

THERAPEUTIC TECHNOLOGIES ACQUIRES RIGHTS TO NEW AIDS DIAGNOSTIC PRODUCT

THERAPEUTIC TECHNOLOGIES ACQUIRES RIGHTS TO NEW AIDS DIAGNOSTIC PRODUCT
 TAMPA, Fla., Aug. 25 /PRNewswire/ -- Therapeutic Technologies, Inc. (NASDAQ: TTII), today announced it has acquired, for its joint venture with Cortisol Medical Research, Inc., of Las Vegas, Nev., the exclusive rights to a new AIDS diagnostic product. The Circadian Rhythm Chart for Cortisol, developed by Dr. Alfred T. Sapse, will provide clinicians with previously unknown information about the real origin of immunosuppression in AIDS and the rationale for use of a new class of drugs in the treatment of AIDS, the cortisol modulators.
 Details of the new AIDS diagnostic chart were presented by Sapse to participants at a meeting on the "AIDS-like disease, without the AIDS virus" held on Aug. 14, 1992, at the Centers for Disease Control (CDC) in Atlanta. The following statement made by Sapse to the meeting participants is provided with this release because of the far-reaching impact on present and future work on AIDS:
 AIDS AND CORTISOL
 A Faulty Laboratory Test
 Prevents Scientists to See the Whole Scope of AIDS
 and What Can Be Done to Correct It
 When we fought in Vietnam, we did it with an arm tied behind the back. Against AIDS and AIDS-like diseases, it is even worse, since we are blindfolded, with the help of a faulty, misleading laboratory test, the cortisol test.
 There are strong indications that behind the AIDS virus, there is a destructive agent, the powerful immuno-suppressor hormone cortisol. Cortisol can induce, all by itself, all the immune changes encountered in AIDS, from the destruction of the T.,NK cells to inducing appearance of Kaposi Sarcoma, Pneumocystis Carinii Pneumonia (PCP), and viruses from cytomegalic (CMV) to Epstein Barr (EBV). Cortisol had been suspected for a long time to play a part in AIDS; however, routine cortisol tests in use for many years in the U.S. would invariably indicate cortisol "normal" while in fact it was not.
 The AIDS virus is a smart one. Like Dr. HIV/Frankenstein, it creates his own cortisol monster, through a strong stimulation of the cortex of the adrenal gland. In AIDS, it is cortisol that seems to induce most of the immune damages, not the AIDS virus.
 If we can control cortisol production, and we can by using cortisol modulators of the 'anticort' type, reported by us in Amsterdam, July 1992, a powerful destructive force in AIDS would be eliminated. In this way the AIDS virus would be severely limited in its capability to do harm.
 What we need is a new cortisol chart that would measure it over a 24-hour period, following the so-called circadian rhythm. At the present time, cortisol is measured in the morning and evening, while the most troublesome changes are occurring during the night.
 A cortisol circadian chart would remove the blindfold we are wearing regarding AIDS, and give us a fair chance to fight it, fully knowing what we are dealing with.
 Cortisol Medical Research, Inc., has developed such a chart. Called the Cortisol Circadian Rhythm Chart, or "The Bat" because of its unusual shape, it can potentially indicate, among others, normal cortisol values, in AIDS-positives, but without symptoms, to elevated levels of cortisol and immune destruction in ARC and AIDS patients. Moreover, it can potentially indicate with a certain degree of accuracy the moment when an AIDS-positive transits from this status to an ARC/AIDS condition.
 The chart, which is not regulated by the FDA, has to go through validation testing before being accepted as an official diagnostic instrument in AIDS. You can speed up this validation and help your patients at the same time by obtaining it free of charge, using it, and reporting your findings to us.
 /end of statement/
 TTI is a manufacturer of therapeutic medical equipment that uses computerized functional electrical stimulation (CFES) to the lower body muscles of a paralyzed person to aid in the prevention, retardation and/or reversal of certain adverse medical conditions by use of active physical therapy. In addition, the company also contracts with hospitals and rehabilitation centers in providing treatment programs for incontinence and computerized FES.
 -0- 8/25/92
 /CONTACT: Richard P. Lange, president of TTI, 813-885-5700/
 (TTII) CO: Therapeutic Technologies, Inc.; Cortisol Medical Research, Inc. ST: Florida, Nevada IN: MTC SU: TNM


GK-OS -- NY035 -- 3001 08/25/92 11:38 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 25, 1992
Words:717
Previous Article:DEERE & COMPANY REPORTS RESULTS
Next Article:LINCOLN-MERCURY REPORTS SALES
Topics:


Related Articles
Surge in products to diagnose and treat STD.
CAMBRIDGE BIOTECH CORPORATION ACQUIRES RIGHTS TO DYNAGEN'S RAPID ANTIBODY TESTS FOR TUBERCULOSIS AND MYCOBACTERIA
PROGENICS PHARMACEUTICALS AWARDED NIH GRANT TO DEVELOP NEW HIV THERAPEUTICS AND CLINICAL ASSAYS
OLYMPUS AMERICA, BEHRING DIAGNOSTICS TO CO-MARKET GENERAL CHEM ANALYZER AND EMIT(R) ASSAYS TO HOSPITAL LABS
AMERICAN BIOGENETIC SCIENCES, INC. RESPONDS TO INVESTOR INQUIRIES
Human Genome Sciences and SmithKline Beecham Streamline Diagnostic Agreement
SLIL Biomedical Formed to Develop New Macrophage-Based Technology Platform
Centocor Reaches Agreement to Sell Oncology Diagnostics Business.
Bayer licenses HIV Group O immunoassay from Roche and Dade Behring.
URRMA Biopharma Inc. Files Patent on the Discovery of a Modified Subclass of IgG Immunoglobulin (Antibodies).

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters